Industry Watch

An Industry Review of 2017 - Part 2

19 December 2017

Looking back at 2017...

As the year draws to a close, we have reached a natural point of reflection here at ChargePoint. 2017 has been yet another significant year for the pharmaceutical industry, which is experiencing a notable period of change. The last few years have seen the industry begin to transform; with the growing use of data and technology, increasing development of high potency products, the enforcement of serilisation regulations in the US, and an ever increasing move towards single-use technology. Importantly for ChargePoint, the biopharma boom continues and therefore the demand for containment, particularly from therapeutic areas such as oncology and hormonal drug products, continues to grow.

An Industry Review of 2017 - Part 1

19 December 2017

Looking back at 2017...

As the year draws to a close, we have reached a natural point of reflection here at ChargePoint. 2017 has been yet another significant year for the pharmaceutical industry, which is experiencing a notable period of change. The last few years have seen the industry begin to transform; with the growing use of data and technology, increasing development of high potency products, the enforcement of serilisation regulations in the US, and an ever increasing move towards single-use technology. Importantly for ChargePoint, the biopharma boom continues and therefore the demand for containment, particularly from therapeutic areas such as oncology and hormonal drug products, continues to grow.

Will it be Clinton? Will it be Trump? Big Pharma in the US is part of the American Dream, but the world needs pioneers

13 April 2016

The US Presidential campaign is stirring up strong feelings on issues like immigration and healthcare with the media’s spotlight trained on Republican Donald Trump – who wants to ‘Make America Great Again’.

Front-runner for the incumbent Democrats, Hillary Clinton is also spending millions pushing her key pledges to voters. She is promising to be a “small business president” which means she wants to give SMEs and entrepreneurs more access to finance, cut through red tape for start-ups and lavish tax reliefs.

Leonardo DiCaprio is a climate change hero but who will save him from the AMR crisis?

03 March 2016
By ChargePoint

When Leonardo DiCaprio won his first Oscar for his role in The Revenant he used the platform to reach a massive worldwide audience to urge more to be done to combat climate change - one of the major scientific issues of our time.

The A-lister’s comments have been well-publicised and the cause he has chosen has been a perennial warning in the media for decades.



Subscribe to RSS Feed